Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of cancer-related deaths among women. Ovarian cancer is often diagnosed too late as four out of five ovarian cancer patients are diagnosed with advanced disease. Early intervention can significantly improve survival rates and is crucial for women who are known to be at higher risk for the disease. ClearNote Health has developed the Avantect Ovarian Cancer Test for women with high risk for ovarian cancer who carry genetic predispositions such as BRCA1, BRCA2 mutations or have a first-degree family member with ovarian cancer.

Sources:
American Cancer Society 2022
SEER12 – https://seer.cancer.gov/statfacts/html/ovary.html (accessed April 14, 2023)
Stage Distribution of SEER Incidence Cases, 2010-2019​
Data on file